Alvotech and Teva Pharmaceuticals announced the US Food and Drug Administration (FDA) has accepted for review a Biologics ...

D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential. Click here to find out why I rate ...

So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval ...

Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review their AVTO6 ...

Vaxxas, a clinical-stage biotechnology company, today announced it has completed enrollment for its Phase I clinical trial of a vaccine against an avian influenza A (H7N9) virus with pandemic ...

Regeneron initiated a quarterly dividend per share that looks somewhat attractive. Despite some recent issues, the biotech ...

Alvotech (ALVO) and Teva Pharmaceuticals (TEVA) announced that the FDA has accepted for review a Biologics License Application, or BLA, for ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top ...

If you purchased or acquired securities in Regeneron between November 2, 2023 and October 30, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877 ...

SNS Insider Reports: Retinal Surgery market to Grow at 6.05% CAGR, Fueled by Minimally Invasive Tools, Aging Population & Increasing diabetic Retinopathy Cases ...